

Brilliant Violet 421™ anti-mouse CD25

Catalog # / Size: 1110215 / 50 µg
 1110165 / 125 µl
 1110170 / 500 µl

Clone: PC61

Isotype: Rat IgG1, λ


Immunogen: IL-2-dependent cytolytic mouse T-cell clone B6.1

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: microg sizes: 0.2 mg/ml
 microL sizes: lot-specific




C57BL/6 mouse splenocytes were stained with CD4 FITC and CD25 (clone PC61) Brilliant Violet 421™ (top) or rat IgG1, κ Brilliant Violet 421™ isotype control (bottom).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the microg size, the suggested use of this reagent is ≤0.125 microg per million cells in 100 microL volume. For immunofluorescent staining using microL sizes, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be

resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: Additional reported applications (for the relevant formats) include:
immunoprecipitation^{1,2}, *in vitro* blocking of IL-2 binding to low- and high-affinity receptors¹⁻⁴, growth inhibition of IL-2-dependent T-cell lines¹⁻⁴, *in vivo* depletion of CD25⁺CD4⁺ Treg cells^{5-8,10}, and immunohistochemical staining of acetone-fixed frozen sections². PC61 antibody recognizes a different epitope than 3C7 antibody (Cat. No. 101902). The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 102014). For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 102040) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/microg).

Application References:

1. Lowenthal JW, *et al.* 1985. *Nature* 315:669. (IP, Block)
2. Ceredig R, *et al.* 1985. *Nature* 314:98. (IP, IHC, Block)
3. Lowenthal JW, *et al.* 1985. *J. Immunol.* 135:3988. (Block)
4. Moreau JL, *et al.* 1987. *Eur. J. Immunol.* 17:929. (Block)
5. Takahashi T, *et al.* 2000. *J. Exp. Med.* 192:303. (Deplete)
6. Onizuka S, *et al.* 1999. *Cancer Res.* 59:3128. (Deplete)
7. Lei TC, *et al.* 2005. *Blood* 105:4865. (Deplete)
8. Pasare C, *et al.* 2004. *Immunity* 21:733. (Deplete)
9. León-Ponte M, *et al.* 2007. *Blood* 109:3139.
10. Cao OW, *et al.* 2007. *Blood* doi:10.1182/blood-2007-02-073304. (Deplete)
11. Benson MJ, *et al.* 2007. *J. Exp. Med.* doi:10.1084/jem.20070719.
12. Schick V, *et al.* 2014. *Gut.* 63:1469. [PubMed](#)

Description: CD25 is a 55 kD glycoprotein also known as the low affinity IL-2R α , Ly-43, p55, or Tac. It is expressed on activated T and B cells, thymocyte subsets, pre-B cells, and T regulatory cells. In association with CD122 (IL-2R β) and CD132 (common γ chain), CD25 forms the high affinity signaling IL-2 receptor.

Antigen References:

1. Taniguchi T, *et al.* 1993. *Cell* 73:5.
2. Waldmann TA. 1991. *J. Biol. Chem.* 266:2681.
3. Read S, *et al.* 2000. *J. Exp. Med.* 192:295.
4. Lowenthal JW, *et al.* 1985. *J. Immunol.*